| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/05/2001 | WO2001047551A2 Eliciting antibodies specific for hepatitis c virus (hcv) |
| 07/05/2001 | WO2001047550A1 Method for treatment of canine distemper |
| 07/05/2001 | WO2001047549A2 Conjugate useful as building block for vaccine preparation |
| 07/05/2001 | WO2001047546A2 Methods and products for tumor immunotherapy using cytokines |
| 07/05/2001 | WO2001047543A2 Activation and inhibition of the immune system |
| 07/05/2001 | WO2001047541A1 Optimized minigenes and peptides encoded thereby |
| 07/05/2001 | WO2001047357A1 One-step system for cleansing, conditioning, and treating the skin |
| 07/05/2001 | WO2001040446A8 Pour-on formulations |
| 07/05/2001 | WO2001011016A3 Vegetal peptones for dna production |
| 07/05/2001 | WO2001010887A3 Multi-functional antimicrobial peptides |
| 07/05/2001 | WO2001009333A3 Immunogenic polypeptide derived from moraxella catarrhalis and uses thereof |
| 07/05/2001 | WO2001009331A3 Moraxella catarrhalis antigen basb125 |
| 07/05/2001 | WO2001009330A3 Moraxella catarrhalis antigen basb121 |
| 07/05/2001 | WO2001003720A9 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 07/05/2001 | WO2001000822A3 Cdna sequences of two interacting fancip2 and fancip3 of the fanconi anemia complementation group a protein |
| 07/05/2001 | WO2001000231A3 Use of cpg as an adjuvant for malaria vaccine |
| 07/05/2001 | WO2000078790A3 Methods for inhibiting hiv replication |
| 07/05/2001 | WO2000078343A3 Method for treating chronic hbv infection |
| 07/05/2001 | WO2000076552A8 Methods and compositions for control of bone formation via modulation of leptin activity |
| 07/05/2001 | WO2000074714A3 Indicators for monitoring the technique of transcutaneous immunization |
| 07/05/2001 | WO2000073348A3 Methods and compositions for inhibiting neoplastic cell growth |
| 07/05/2001 | WO2000070046A3 Secreted polypeptides and corresponding polynucleotides |
| 07/05/2001 | WO2000069896A3 Molecular interactions in haematopoietic cells |
| 07/05/2001 | WO2000061622A3 Genes associated with diseases of the kidney |
| 07/05/2001 | WO2000061621A3 Flea head, nerve cord, hindgut and malpighian tubule nucleic acid molecules, proteins and uses thereof |
| 07/05/2001 | WO2000059942A3 Human obesity protein binding protrein-2 homolog and uses thereof |
| 07/05/2001 | WO2000034483A9 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 07/05/2001 | WO2000023114A9 Polymer conjugates of interferon beta- 1a and their uses |
| 07/05/2001 | US20010007022 An antibody which binds procalcitonin but not free calcitonin, free katacalcin and free N-procalcitonin; used as an in vitro or in vivo diagnostic agent |
| 07/05/2001 | US20010007021 Monoclonal antibody, antigen-binding region of which competitively inhibits immunospecific binding of monoclonal antibody produced by hybridoma R7.6.2 having ATCC accession number 13 13 13 13 to target epitope; use in organ transplants |
| 07/05/2001 | US20010007020 Antibodies that bind to the nidogen-binding domain of laminin, their production and use |
| 07/05/2001 | US20010007017 For preventing AIDS or slowing down its progression |
| 07/05/2001 | US20010006950 Include genetic vaccine components that confer the ability to direct an immune response so as to acheive an optimal response to vaccination |
| 07/05/2001 | US20010006947 Methods of administering adenoviral vectors |
| 07/05/2001 | US20010006944 Treating noninvasive fungus-induced rhinosinusitis by mucoadministering an antifungal agent; culturing noninvasive fungus from a mammalian mucus sample for antigen/antibody production; apparatus for collecting nasal mucus |
| 07/05/2001 | US20010006942 Inducing an immune response against a chemokine receptor molecule by administering an immunogenic chemokine receptor polypeptide from an extracellular region of a chemokine receptor molecule; treating inflammation, multiple sclerosis |
| 07/05/2001 | US20010006939 Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions |
| 07/05/2001 | US20010006816 Novel property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses |
| 07/05/2001 | US20010006815 Novel property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses |
| 07/05/2001 | US20010006814 Chemical modification |
| 07/05/2001 | US20010006799 Histidine kinase polypeptides |
| 07/05/2001 | US20010006798 Novel FtsL |
| 07/05/2001 | US20010006792 Immunomodulatory properties |
| 07/05/2001 | US20010006776 Methods for treatment of hiv and other infections using a t cell or viral activator and anti-retroviral combination therapy |
| 07/05/2001 | US20010006642 Delivering antigens or biologically active polypeptides to a subject in need of same by administering to the subject a non-invasive or non-pathogenic bacterium which expresses the antigens or polypeptides |
| 07/05/2001 | US20010006641 Immunological reagents and diagnostic methods for the detection of human immunodeficiency virus type 2 utilizing multimeric forms of the envelope proteins GP300, P200, and P90/80 |
| 07/05/2001 | US20010006639 Immunogenic peptides from the HPV E7 protein |
| 07/05/2001 | US20010006635 Decreasing localized inflammatory responses in a tissue of a patient by administering to said patient heparinase enzyme in an effective amount sufficient to decrease said localized inflammatory response |
| 07/05/2001 | US20010006631 Alloactivated lymphocytes in a pharmaceutical excipient; immunotherapy |
| 07/05/2001 | CA2397952A1 Method for treatment of canine distemper |
| 07/05/2001 | CA2397710A1 Streptococcus pyogenes virulence genes and proteins and their use |
| 07/05/2001 | CA2396029A1 Use of a native epitope for selecting evolved binding members from a library of mutants of a protein capable of binding to said epitope |
| 07/05/2001 | CA2395535A1 Method for the production of vitamin a |
| 07/05/2001 | CA2395423A1 P. gingivalis antigenic composition |
| 07/05/2001 | CA2395382A1 Attenuated microorganisms for the treatment of infection |
| 07/05/2001 | CA2395242A1 Composition for inhibiting macrophage activity |
| 07/05/2001 | CA2395003A1 Dioxygenases catalyzing the asymetric cleavage of beta-carotene |
| 07/05/2001 | CA2394880A1 Activation and inhibition of the immune system |
| 07/05/2001 | CA2394748A1 Optimized minigenes and peptides encoded thereby |
| 07/05/2001 | CA2394295A1 Antibodies against plasma cells |
| 07/05/2001 | CA2392703A1 Human heparanase-related polypeptide and nucleic acid |
| 07/04/2001 | EP1113073A2 Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |
| 07/04/2001 | EP1112747A1 Salmonella vaccine not inducing antibodies against flagellin or flagella |
| 07/04/2001 | EP1112746A2 Eimeria strains as Coccidiosis vaccines |
| 07/04/2001 | EP1112497A1 Ykl-40 as a marker and prognostic indicator for cancers |
| 07/04/2001 | EP1112495A2 Antibacterial disaccharide derivatives |
| 07/04/2001 | EP1112368A1 Use of protein kinase kiaa0551 as pharmaceutical |
| 07/04/2001 | EP1112366A1 Polynucleotides and polypeptides basb033 from neisseria meningitidis and their uses |
| 07/04/2001 | EP1112365A2 Human and murine g-protein-coupled edg6 receptor (endothelial differentiation gene) and use of same |
| 07/04/2001 | EP1112364A2 Stomach polypeptide zsig28 |
| 07/04/2001 | EP1112361A2 Promotion or inhibition of angiogenesis and cardiovascularization |
| 07/04/2001 | EP1112358A2 Dna sequence encoding oncofetal ferritin protein |
| 07/04/2001 | EP1112350A2 Temperature-sensitive and cold-adapted human parainfluenza virus type 2 (hpiv-2) and vaccines based on such virus |
| 07/04/2001 | EP1112286A1 Secreted proteins and polynucleotides encoding them |
| 07/04/2001 | EP1112088A1 Method for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor |
| 07/04/2001 | EP1112086A1 Antibodies to c3b(i) for delivery of diagnostic and therapeutic agents to cancer cells |
| 07/04/2001 | EP1112085A1 Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody |
| 07/04/2001 | EP1112084A1 Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
| 07/04/2001 | EP1112083A2 Use of an angiogenic factor for the treatment of microvascular angiopathies |
| 07/04/2001 | EP1112078A2 New use |
| 07/04/2001 | EP0896538B1 Use of activity inhibiting dipeptidyl peptidase iv effectors for lowering the blood glucose level in mammals |
| 07/04/2001 | EP0789586B1 Compounds for the prevention and treatment of helminth infections |
| 07/04/2001 | EP0679187B2 Process for recovering native, oligomeric, glycosylated ectodomains of viral membrane proteins, their use, in particular as vaccine against hiv |
| 07/04/2001 | CN1302330A Differential cytotoxicity of alternative forms of rotavirus nonstructural protein 4 |
| 07/04/2001 | CN1301866A Full gene cloning of horse infectious anemia virus representating virus strain and its use |
| 07/04/2001 | CN1301572A Adjuvant composition for vaccine |
| 07/04/2001 | CN1301571A Development method for pylorus helicobacterium adhesion agent HpaA gene engineering vaccine |
| 07/04/2001 | CN1068009C Isolated nucleic acid molecules as members of the mage-XP family and uses thereof |
| 07/03/2001 | US6255471 CRFG-1b, a target and marker for chronic renal failure |
| 07/03/2001 | US6255470 Isolated nucleic acid molecule encoding an esophageal cancer associated antigen |
| 07/03/2001 | US6255467 Human blood bacterium |
| 07/03/2001 | US6255277 Localized use of nitric oxide-adducts to prevent internal tissue damage |
| 07/03/2001 | US6255107 An antibody reacting with a cell surface antigen expressed on tryptase and chymase positive human mast cells; treatment of allergic disease, bronchial asthma, allergic rhinitis |
| 07/03/2001 | US6255105 Nucleotide and deduced amino acid sequences of tumor gene Int6 |
| 07/03/2001 | US6255097 Immunogenic composition using spontaneous dna recombination in a live vaccine, creating two subpopulations; the infection process induces an immune respone while the formation of additional antigens is an effective immune response; vaccines |
| 07/03/2001 | US6255078 Nucleotide sequence which codes polypeptide associated with viral protein; for the prevention of viral infection in animals |
| 07/03/2001 | US6255072 Nucleotide sequences coding proteolytic polypeptide; for use as diagnostic tool; for the prevention of bacterial infection |
| 07/03/2001 | US6255055 Diagnosing breast cancer; evaluate breast tissue for preferential polypeptide expression, compare with expression in noncancerous tissue, an amplified presence of preferential polypeptide in tissue indicates cancer |
| 07/03/2001 | US6254875 Methods for use of OMP26 from Haemophilus influenzae |
| 07/03/2001 | US6254873 Dengue virus protection |